Xenon Pharmaceuticals Statistics
Total Valuation
XENE has a market cap or net worth of $3.09 billion. The enterprise value is $2.25 billion.
Important Dates
The next estimated earnings date is Thursday, February 27, 2025, after market close.
| Earnings Date | Feb 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XENE has 76.24 million shares outstanding. The number of shares has increased by 15.16% in one year.
| Current Share Class | 76.24M |
| Shares Outstanding | 76.24M |
| Shares Change (YoY) | +15.16% |
| Shares Change (QoQ) | +0.33% |
| Owned by Insiders (%) | 0.13% |
| Owned by Institutions (%) | 92.84% |
| Float | 70.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.80 |
| P/TBV Ratio | 3.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.21, with a Debt / Equity ratio of 0.01.
| Current Ratio | 22.21 |
| Quick Ratio | 22.06 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.75% and return on invested capital (ROIC) is -21.95%.
| Return on Equity (ROE) | -29.75% |
| Return on Assets (ROA) | -21.19% |
| Return on Invested Capital (ROIC) | -21.95% |
| Return on Capital Employed (ROCE) | -31.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$823,892 |
| Employee Count | 259 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -446,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.94% in the last 52 weeks. The beta is 1.21, so XENE's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | -12.94% |
| 50-Day Moving Average | 40.28 |
| 200-Day Moving Average | 40.37 |
| Relative Strength Index (RSI) | 50.76 |
| Average Volume (20 Days) | 419,234 |
Short Selling Information
The latest short interest is 3.59 million, so 4.71% of the outstanding shares have been sold short.
| Short Interest | 3.59M |
| Short Previous Month | 3.48M |
| Short % of Shares Out | 4.71% |
| Short % of Float | 5.10% |
| Short Ratio (days to cover) | 7.75 |
Income Statement
| Revenue | n/a |
| Gross Profit | -192.00M |
| Operating Income | -255.52M |
| Pretax Income | -199.34M |
| Net Income | -213.39M |
| EBITDA | -252.74M |
| EBIT | -255.52M |
| Earnings Per Share (EPS) | -$2.82 |
Full Income StatementBalance Sheet
The company has $654.02 million in cash and $9.79 million in debt, giving a net cash position of $793.55 million or $10.41 per share.
| Cash & Cash Equivalents | 654.02M |
| Total Debt | 9.79M |
| Net Cash | 793.55M |
| Net Cash Per Share | $10.41 |
| Equity (Book Value) | 797.81M |
| Book Value Per Share | 10.53 |
| Working Capital | 629.94M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$156.62 million and capital expenditures -$2.37 million, giving a free cash flow of -$158.99 million.
| Operating Cash Flow | -156.62M |
| Capital Expenditures | -2.37M |
| Free Cash Flow | -158.99M |
| FCF Per Share | -$2.09 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |